Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Harousseau, J L ^a   Dreyling, M ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INTERFERON; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADVANCED CANCER; ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW BIOPSY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; ELECTROPHORESIS; FOLLOW UP; GAMMOPATHY; HUMAN; IMMUNOLOGICAL PROCEDURES; LOW DRUG DOSE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SURVIVAL RATE; SYMPTOM; TREATMENT RESPONSE; X RAY;

CALCIUM; CREATININE; DRUG THERAPY, COMBINATION; EUROPE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INCIDENCE; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77954339963     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq178     Document Type: Article

References (21)

1. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2002; 121: 749-757.
2. Attal M, Harousseau JL. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
3. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
4. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108: 3289-3294.
5. Barlogie B, Tricot T, Anaissie E et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 35: 1021-1030.
6. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
7. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
8. Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
9. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
10. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
11. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
12. Harousseau JL, Moreau P. Autologous stem cell transplantation for multiple myeloma N Engl J Med 2009; 360: 41-50.
13. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete remission in multiple myeloma Blood 2009; 114: 3139-3146.
14. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 70 years of age: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664-3670.
15. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
16. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for multiple myeloma: 10 years later. Blood 2008; 112: 3107-3114.
17. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multpiple myeloma: an open randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
18. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
19. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
20. Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793.
21. Weber DM, Chen C, Nievisky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.